

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

LIM1215

RRID:CVCL_2574

Type: Cell Line

Proper Citation

RRID:CVCL_2574

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2574

Proper Citation: RRID:CVCL_2574

Description: Cell line LIM1215 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: [PMID:1427983](#), [PMID:3857372](#), [PMID:9328464](#), [PMID:9515795](#), [PMID:11416159](#), [PMID:12615714](#), [PMID:19378335](#), [PMID:20570890](#), [PMID:22722830](#), [PMID:23458625](#), [PMID:24295106](#), [PMID:24755471](#), [PMID:25623215](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:28854368](#), [PMID:30894373](#)

Comments: Population: Caucasian., From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LIM1215

Synonyms: Lim1215, LIM 1215, LIM-1215

Cross References: BTO:BTO_0001916, EFO:EFO_0022437, BioSample:SAMN07624413, cancercellines:CVCL_2574, CBA:CBA-0161, Cell_Model_Passport:SIDM00014, ColonAtlas:LIM1215, Cosmic:869795, Cosmic:1184335, Cosmic:1238050, Cosmic:1479632, Cosmic:1482515, Cosmic:1486135, Cosmic:1524335, Cosmic:1676746, Cosmic:1805257, Cosmic:2301991, Cosmic:2667967,

Cosmic:2787550, Cosmic:2841366, Cosmic-CLP:2162949, DepMap:ACH-001546, ECACC:10092301, GDSC:869795, GDSC:2162949, GEO:GSM741246, GEO:GSM1346878, GEO:GSM1448118, IARC_TP53:22464, Pharmacodb:LIM1215_836_2019, PRIDE:PXD000120, PRIDE:PXD005235, Wikidata:Q54902517

ID: CVCL_2574

Record Creation Time: 20220427T220727+0000

Record Last Update: 20260905T181026+0000

Ratings and Alerts

No rating or validation information has been found for LIM1215.

No alerts have been found for LIM1215.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. EMBO molecular medicine, 18(6), 2322.

Asmanidou S, et al. (2026) BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. Cell death & disease, 17(1), 187.

Jacob J, et al. (2025) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. Cancer research, 85(5), 973.

High PC, et al. (2025) Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. Cell reports. Medicine, 102363.

Mohammadi M, et al. (2025) Cyclin-dependent kinase 9 inhibitors as oncogene signaling modulators in combination with targeted therapy for the treatment of colorectal cancer. bioRxiv : the preprint server for biology.

High PC, et al. (2025) Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. bioRxiv : the preprint server for biology.

Deng J, et al. (2024) The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas. *EMBO molecular medicine*, 16(9), 2080.

Jacob J, et al. (2024) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer. *bioRxiv : the preprint server for biology*.

Johnson CW, et al. (2022) Regulation of GTPase function by autophosphorylation. *Molecular cell*, 82(5), 950.

Su W, et al. (2022) ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. *Molecular cell*, 82(13), 2443.

Rau A, et al. (2022) Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer. *Molecular cancer therapeutics*, 21(5), 799.

Vitiello PP, et al. (2021) Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. *Journal of experimental & clinical cancer research : CR*, 40(1), 15.

Urban H, et al. (2020) Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer. *Cancers*, 12(10).